You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Are You Up to Date on the Management of Schizophrenia?

  • Authors: John Lauriello, MD
  • CME / ABIM MOC Released: 5/17/2022
  • Valid for credit through: 5/17/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, and nurse practitioners.

The goal of this activity is that learners will be better able to self-assess their learning needs related to the management of schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging treatments for schizophrenia
  • Self-assess learning needs related to
    • Treatment considerations for schizophrenia management


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • John Lauriello, MD

    Chair and Professor
    Department of Psychiatry and Human Behavior Sidney Kimmel Medical
    Thomas Jefferson University
    Philadelphia, Pennsylvania


    Disclosure: John Lauriello, MD, has the following relevant financial relationships:
    Consultant or advisor for: BioXel Therapeutics; Orexo
    Other: Data management Safety Boards for Avanair Therapeutics; BioXcel Therapeutics; Karuna Therapeutics


  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC


    Disclosure: Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.

  • Megan Breuer, PhD

    Medical Writer, Medscape, LLC


    Disclosure: Megan Breuer, PhD, has the following relevant financial relationship: Advisor/consultant Paratek Pharmaceuticals, Inc. (former)

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Are You Up to Date on the Management of Schizophrenia?

Authors: John Lauriello, MDFaculty and Disclosures

CME / ABIM MOC Released: 5/17/2022

Valid for credit through: 5/17/2023



  1. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third edition. Washington, DC: American Psychiatric Association. 2021.
  2. Bugarski-Kirola D, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9:41-58.
  3. Alkan E, et al. Cognitive impairment in schizophrenia: relationships with cortical thickness in fronto-temporal regions, and dissociability from symptom severity. NPJ Schizophr. 2021;7:20.
  4. Heffernan MLR, et al. Ulotaront: A TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2022;13:92-98.
  5. Nair PC, et al. Trace amine-associated receptor 1 (TAAR1): Molecular and clinical insights for the treatment of schizophrenia and related comorbidities. ACS Pharmacol Transl Sci. 2022;5:183-188.
  6. Correll CU, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: A 24-week phase 3 study. Am J Psychiatry. 2020;177:1168-1178.
  7. Marteene W, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019;18:1149-1160.
  8. Woerner MG, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160:1514-1516.
  9. Brannan SK, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717-726.
  10. Acosta FJ, et al. Medication adherence in schizophrenia. World J Psychiatry. 2012;2:74-82.
  11. Kim J, et al. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. Neuropharmacology. 2020;168:107634.
  12. Ward K, et al. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy. Expert Opin Investig Drugs. 2020;29:245-257.
  13. BioXcel Therapeutics announces FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel. News release. April 6, 2022.
  14. Debrey SM, et al. Tardive dyskinesia: Spotlight on current approaches to treatment. Focus (Am Psychiatr Publ). 2021;19:14-23.
  15. Kahn RS, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.
  16. Petersen L, et al. Paternal age at birth of first child and risk of schizophrenia. Am J Psychiatry. 2011;168:82-88.
  17. Correll CU, et al. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res. 2021;228:198-205.
« Return to: Are You Up to Date on the Management of Schizophrenia?
  • Print